Search
Close this search box.
Search
Close this search box.

Hemo Alliance Newsletters

Legal Update, February 2022

Legal Update

Grants Management that Makes Sense
by Elizabeth “Issie” Karan, Legal Counsel

Hemophilia Treatment Centers (HTCs) often must grapple with grey areas when it comes to compliance with the rules for their federal funding. The Hemophilia Alliance team works to demystify these guardrails and steer HTCs towards effective operations. We want to highlight an area of grants management that often creates confusion.

Many HTCs are lucky enough to accrue a balance of program income during their grant period. This is not common for federally funded grants. As a result, many accountants familiar with other grant programs expect HTCs to zero out their accounts at the end of the fiscal year. Because revenue cycles involving high-cost therapies can be volatile, HTCs should consider prudent accounting practices. The Uniform Grants Guidance allows federal grantees to carry forward balances to subsequent periods of performance with permission from their awarding agency. The Maternal and Child Health Bureau (MCHB), which oversees the regional HTCs and the grant program more generally, has the authority to allow this practice.

At 45 CFR § 75.308 (d)(3), Revision of budget and program plans, the UGG states:

“… HHS awarding agencies are authorized, at their option, to waive prior written approvals… [s]uch waivers may include authorizing recipients to … [c]arry forward unobligated balances to subsequent periods of performance…”

If HTCs do not currently carry forward unobligated balances or receive pressure not to, we recommend that you speak with your regional grantee about your policy. HTCs should embrace grants management policies that sustain their comprehensive care model for generations of bleeding and clotting disorder patients to come.

Also in this Issue…

Notes from Joe
· Harmony in Hemophilia

Washington Update
· Join us for the Alliance Hill Day!

Payer Update
· Request for Coverage of Desmopressin Acetate Nasal Spray (DDAVP)

Alliance Update
· 1st Annual Hemophilia Alliance Pharmacist CE Conference

Team Alliance Contact Information

We work for you! Please don’t hesitate to contact any of us with any questions or concerns:

NameEmailPhone
Jeff Blakejeff@hemoalliance.org317-657-5913
Jennifer Borrillo, MSW, LCSW, MBAborrillo@hemoalliance.org504-376-5282
Jeff Amondamond@hemoalliance.org608-206-3132
Jennifer Andersjennifer@hemoalliance.org954-218-8509
Angela Blue, MBAangela@hemoalliance.org651-308-3902
Karen Bowe-Hausekaren@hemoalliance.org717-571-0266
Zack Duffyzack@hemoalliance.org503-804-2581
Michael B. GlombMGlomb@ftlf.com202-466-8960
Johanna Gray, MPAjgray@artemispolicygroup.com703-304-8111
Kiet Huynhkiet@hemoalliance.org917-362-1382
Elizabeth Karanelizabeth@karanlegalgroup.com612-202-3240
Kollet Koulianos, MBAkollet@hemoalliance.org309-397-8431
Roland P. Lamy, Jr.roland@hemoalliance.org603-491-0853
Dr. George L. Oestreich, Pharm.D., MPAgeorge@gloetal.com573-230-7075
Theresa Parkertheresa@hemoalliance.org727-688-2568
Mark Plencnermark@hemoalliance.org701-318-2910
Ellen Rikereriker@artemispolicygroup.com202-257-6670